Improving therapeutic adherence: the Pharmacy of the Duilio Casula Polyclinic together with the University of Cagliari are developing a project that uses Artificial Intelligence (AI) to personalize therapies, evaluate the efficacy and safety of monoclonal antibodies (AM) indicated in migraine prophylaxis.
The work of the experts from Cagliari was brought to the GoAhead Contest (a team competition dedicated to Pharmacists and their multi-professional teams) at the Stazione Leopolda in Florence, and uses the capabilities of AI to improve therapeutic adherence and reduce the time needed to evaluate the effectiveness of a treatment, minimizing the side effects of drugs prescribed to treat migraines. The Cagliari team was among the finalists and triumphed as the winner of the contest .
The work was presented by Dr. Arianna Cadeddu, director of the Pharmacy of the Duilio Casula Polyclinic, by Dr. Giacomo Bertolino, pharmacist of the AOU of Cagliari, by the specialist pharmacists Silvia Vargiu and Alessandro Zaru and by Professor Diego Reforgiato Recupero, of the Department of Mathematics and Computer Science of the University of Cagliari, expert in AI.
The main objective of the project, explains Dr. Arianna Cadeddu, «is to evaluate the efficacy and safety of monoclonal antibodies in the prevention and treatment of migraine, with a focus on the integration of artificial intelligence to personalize therapies : early identification of patients who may be poorly adherent to therapy or non-persistent».
The project, furthermore, continues Dr. Cadeddu, «aims to evaluate the implementation of a digital platform with the help of AI algorithms that would give pharmacists and prescribing clinicians a monitoring tool for patients in order to reduce low and intermediate adherence, and increase persistence to follow-up. The tool would select patients to monitor more carefully to maximize the effectiveness of the therapy, reduce side effects and optimize healthcare resources, thanks to personalized checks that take into account the individual characteristics of the patients».
AI, concludes Dr. Arianna Cadeddu, «can monitor in real time the progress of symptoms, the effectiveness of treatments and therapeutic adherence through wearable devices and smartphone apps, offering a personalized and dynamic approach to disease management».
The drugs considered for the project are distributed by the Pharmacy of the Duilio Casula Polyclinic through direct distribution.
(Online Union)